Brady S Laughlin1, Molly M Petersen2, Nathan Y Yu1, Justin D Anderson1, William G Rule3, Mitesh J Borad4, Bashar A Aqel5,6, Mohamad B Sonbol4, Amit K Mathur6,7, Adyr A Moss6,7, Tanios S Bekaii-Saab4, Daniel H Ahn4,8, Todd A DeWees2,3, Terence T Sio3, Jonathan B Ashman3. 1. Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Phoenix, Arizona, USA. 2. Clinical Trials and Biostatistics, Mayo Clinic, Scottsdale, Arizona, USA. 3. Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix, Arizona, USA. 4. Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, Arizona, USA. 5. Division of Gastroenterology and Hepatology, Mayo Clinic Hospital, Phoenix, Arizona, USA. 6. Transplant Center, Mayo Clinic Hospital, Phoenix, Arizona, USA. 7. Division of Transplant and Hepatobiliary Surgery, Mayo Clinic Hospital, Phoenix, Arizona, USA. 8. Mayo Clinic Cancer Center, Mayo Clinic Hospital, Phoenix, Arizona, USA.
Abstract
Background: We report our experience with 3 strategies for treating hilar and extrahepatic cholangiocarcinoma (CCA) including chemoradiotherapy: neoadjuvant chemoradiotherapy (nCRT) and orthotopic liver transplant, surgical resection and adjuvant chemoradiotherapy (aCRT), and definitive chemoradiotherapy (dCRT). Methods: We included patients treated from 1998 through 2019. Kaplan-Meier estimates, log-rank testing, and univariate/multivariate Cox models were used to assess outcomes (local progression-free survival, disease-free survival, and overall survival). Results: Sixty-five patients (nCRT, n=20; aCRT, n=16; dCRT, n=29) met inclusion criteria [median (range) age 65 years (27-84 years)]. Median posttreatment follow-up was 19.1 months (0.8-164.8 months) for all patients and 38.6, 24.3, and 9.0 months for the nCRT, aCRT, and dCRT groups, respectively. At 3 and 5 years, overall survival was 78% and 59% for the nCRT group; 47% and 35%, aCRT group; and 11% and 0%, dCRT group. Compared with the dCRT group, the nCRT group (hazard ratio =0.13, 95% CI: 0.05-0.33) and the aCRT group (hazard ratio =0.29, 95% CI: 0.14-0.64) had significantly improved overall survival (P<0.001). The 5-year local progression-free survival (50% nCRT vs. 30% aCRT vs. 0% dCRT, P<0.001) and 5-year disease-free survival (61% nCRT vs. 30% aCRT vs. 0% dCRT, P=0.01) were significantly better for strategies combined with surgery. Conclusions: Outcomes for patients with extrahepatic CCA were superior for those who underwent nCRT/orthotopic liver transplant or postsurgical aCRT than for patients treated with dCRT. The excellent outcomes after nCRT/orthotopic liver transplant provide additional independent data supporting the validity of this strategy. The poor survival of patients treated with dCRT highlights a need for better therapies when surgery is not possible. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: We report our experience with 3 strategies for treating hilar and extrahepatic cholangiocarcinoma (CCA) including chemoradiotherapy: neoadjuvant chemoradiotherapy (nCRT) and orthotopic liver transplant, surgical resection and adjuvant chemoradiotherapy (aCRT), and definitive chemoradiotherapy (dCRT). Methods: We included patients treated from 1998 through 2019. Kaplan-Meier estimates, log-rank testing, and univariate/multivariate Cox models were used to assess outcomes (local progression-free survival, disease-free survival, and overall survival). Results: Sixty-five patients (nCRT, n=20; aCRT, n=16; dCRT, n=29) met inclusion criteria [median (range) age 65 years (27-84 years)]. Median posttreatment follow-up was 19.1 months (0.8-164.8 months) for all patients and 38.6, 24.3, and 9.0 months for the nCRT, aCRT, and dCRT groups, respectively. At 3 and 5 years, overall survival was 78% and 59% for the nCRT group; 47% and 35%, aCRT group; and 11% and 0%, dCRT group. Compared with the dCRT group, the nCRT group (hazard ratio =0.13, 95% CI: 0.05-0.33) and the aCRT group (hazard ratio =0.29, 95% CI: 0.14-0.64) had significantly improved overall survival (P<0.001). The 5-year local progression-free survival (50% nCRT vs. 30% aCRT vs. 0% dCRT, P<0.001) and 5-year disease-free survival (61% nCRT vs. 30% aCRT vs. 0% dCRT, P=0.01) were significantly better for strategies combined with surgery. Conclusions: Outcomes for patients with extrahepatic CCA were superior for those who underwent nCRT/orthotopic liver transplant or postsurgical aCRT than for patients treated with dCRT. The excellent outcomes after nCRT/orthotopic liver transplant provide additional independent data supporting the validity of this strategy. The poor survival of patients treated with dCRT highlights a need for better therapies when surgery is not possible. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart Journal: Ann Surg Date: 2001-10 Impact factor: 12.969
Authors: Silvia Bisello; Milly Buwenge; Andrea Palloni; Rosa Autorino; Francesco Cellini; Gabriella Macchia; Francesco Deodato; Savino Cilla; Giovanni Brandi; Luca Tagliaferri; Silvia Cammelli; Vincenzo Valentini; Alessio G Morganti; Gian C Mattiucci Journal: Anticancer Res Date: 2019-06 Impact factor: 2.480
Authors: David J Rea; Julie K Heimbach; Charles B Rosen; Michael G Haddock; Steven R Alberts; Walter K Kremers; Gregory J Gores; David M Nagorney Journal: Ann Surg Date: 2005-09 Impact factor: 12.969
Authors: Anna Torgeson; Shane Lloyd; Dustin Boothe; George Cannon; Ignacio Garrido-Laguna; Jonathan Whisenant; Mark Lewis; Robin Kim; Courtney Scaife; Randa Tao Journal: Ann Surg Oncol Date: 2017-10-17 Impact factor: 5.344
Authors: Julie K Heimbach; Gregory J Gores; Michael G Haddock; Steven R Alberts; Scott L Nyberg; Michael B Ishitani; Charles B Rosen Journal: Semin Liver Dis Date: 2004-05 Impact factor: 6.115